Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Fineline Cube Apr 13, 2026
Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Fineline Cube Apr 13, 2026
Company Deals Drug

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo

Fineline Cube Apr 13, 2026
Company Drug

AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease

Fineline Cube Apr 13, 2026
Company Deals

Luye Pharma Grants Myung In Pharm Rights to Rivastigmine Patch for Alzheimer’s Treatment in South Korea

Fineline Cube Feb 6, 2024

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with...

Company Deals

Abbisko Therapeutics Secures $70 Million Upfront Payment in Licensing Deal with Merck KGaA

Fineline Cube Feb 6, 2024

Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has declared the successful conclusion of...

Company Drug

Joincare Pharmaceuticals Gets Green Light for Semaglutide Biosimilar Clinical Trial

Fineline Cube Feb 6, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical entity, has announced that...

Company

Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues

Fineline Cube Feb 6, 2024

Japanese pharmaceutical corporation Astellas Pharma Inc., (TYO: 4503) has announced its financial results for the...

Company Drug

CSPC Pharmaceutical’s rhTNK-tPA Gets NMPA Approval for Acute Ischemic Stroke Treatment

Fineline Cube Feb 5, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Roche’s Faricimab Shows Sustained Vision Benefits in Phase III Study for Retinal Vein Occlusion

Fineline Cube Feb 5, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has released interim Phase III data for its bispecific...

Policy / Regulatory

CDE Reports 35.84% Increase in Drug Filings for 2023 with Focus on Innovation and Rare Diseases

Fineline Cube Feb 5, 2024

The Center for Drug Evaluation (CDE) has released its annual drug review report for 2023,...

Company Drug

J&J’s Gene Therapy for X-linked Retinitis Pigmentosa Receives CDE Nod for Breakthrough Designation

Fineline Cube Feb 5, 2024

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...

Company

German Tech Giant Merck Launches Digital Hub in Singapore to Boost Healthcare and Semiconductor Research

Fineline Cube Feb 5, 2024

Merck KGaA (ETR: MRK), a leading German technology company, last week inaugurated a digital hub...

Company Drug

Johnson & Johnson’s Talquetamab and Daiichi Sankyo’s Enhertu Eye Priority Review in China

Fineline Cube Feb 5, 2024

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...

Company

Biogen Discontinues Aduhelm Development, Redirects Focus to Other Alzheimer’s Therapies

Fineline Cube Feb 5, 2024

Biogen (NASDAQ: BIIB) has announced its decision to discontinue the development and commercialization of its...

Company

Beckton Dickinson’s Q1 Results Affected by Volume-Based Procurement, Life Sciences Growth

Fineline Cube Feb 5, 2024

US-based medical technology company Beckton Dickinson (BD; NYSE: BDX) has reported its financial results for...

Company Drug

SciClone and Menarini File for Import License of Antibacterial Drug Vaborem in Macau

Fineline Cube Feb 5, 2024

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that its Italy-based strategic partner Menarini has submitted...

Company Deals

Baidu Health Partners with Souyao to Boost Offline Pharmacy Services in China

Fineline Cube Feb 5, 2024

Baidu Health has entered into a partnership with Beijing-based pharmaceutical business service provider Souyao. The...

Company

AbbVie Reports $54.3 Billion in 2023 Revenues Amid Humira Erosion and Segment Variability

Fineline Cube Feb 4, 2024

AbbVie (NYSE: ABBV) reported revenues of $54.3 billion for 2023, reflecting a 5.9% year-on-year decline...

Policy / Regulatory

US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions

Fineline Cube Feb 4, 2024

A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...

Company Drug

Biotech Pharmaceutical Secures Approval for Nimotuzumab in Head and Neck Cancer Treatment

Fineline Cube Feb 4, 2024

Sino-Cuban joint venture Biotech Pharmaceutical Limited (BPL) has secured another indication approval in China for...

Company Drug

BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity

Fineline Cube Feb 4, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding...

Policy / Regulatory R&D

China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates

Fineline Cube Feb 4, 2024

China’s National Cancer Center (NCC) has released the latest national cancer statistics, approved by the...

Company Deals

Johnson & Johnson’s Kenvue Partners with Tencent for Integrated Health Services in China

Fineline Cube Feb 4, 2024

Johnson & Johnson (J&J, NYSE: JNJ)’s consumer health spinoff Kenvue and its Chinese partner Tencent...

Posts pagination

1 … 387 388 389 … 649

Recent updates

  • Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo
  • AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease
  • IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers
  • CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine
  • Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo

Company Drug

AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease

Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.